The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes

Sponsor
University of Malaya
Study ID
NCT02964715
Phase
PHASE4
Status
Unknown

Conditions

  • NAFLD
  • Type2 Diabetes

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Non-Alcoholic Fatty Liver Disease( NAFLD) is common in patients with type 2 diabetes. Empagliflozin, an FDA-approved oral medication used to treat type 2 diabetes, has been shown to reduce production and deposition of fat in the liver in animal experiments. There is little published evidence that this is so in Asian patients with type 2 diabetes. The investigators designed this pilot study to determine if use of empagliflozin for 6 months in patients with type 2 diabetes can improve scan, blood marker and biopsy features of NAFLD.

Key Dates

Start date
Nov 30, 2016
Status verified
May 2017
Primary completion
Nov 30, 2018
Completion
Nov 30, 2018

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Interventional arm
    Patients with NAFLD and Type 2 Diabetes prescribed 25mg empagliflozin(JARDIANCE) daily for 6 months

Primary Outcome Measure

Change in histological Grade as evaluated with Non-alcoholic Steatohepatitis Clinical Research Network Scoring System [ Time Frame: baseline, 6 months ]

Central Contacts

Related Studies